TaiGen starts burixafor trial in China

TaiGen Biopharmaceuticals Holdings Ltd. (GreTai:4157) began a Phase I/II trial in China of burixafor ( TG-0054), a CXC chemokine receptor 4 ( CXCR4) inhibitor, to treat relapsed or refractory acute myelogenous leukemia (AML).

The open-label, dose-finding study in up to 15 patients will examine the safety and efficacy of burixafor in combination with fludarabine and cytarabine. The study's endpoints include complete response (CR), disease-free survival (DFS), and overall survival (OS). TaiGen has completed a Phase II study of burixafor in the U.S. to treat multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), and Hodgkin's disease. ...